UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 329

Sortiert nach

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

Archives of pathology & laboratory medicine (1976), 2019-03, Vol.143 (3), p.330-337

2019

Link zum Volltext

Verfügbarkeit prüfen

Discovery of MK-8719, a Potent O‑GlcNAcase Inhibitor as a Potential Treatment for Tauopathies

Journal of medicinal chemistry, 2019-11, Vol.62 (22), p.10062-10097

2019

Link zum Volltext

Verfügbarkeit prüfen

Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy

PloS one, 2018-04, Vol.13 (4), p.e0195486-e0195486

2018

Link zum Volltext

Verfügbarkeit prüfen

Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort

Journal of Alzheimer's disease, 2015-01, Vol.44 (2), p.525

2015

Link zum Volltext

Verfügbarkeit prüfen

AMPA Receptor Downscaling at the Onset of Alzheimer's Disease Pathology in Double Knockin Mice

Proceedings of the National Academy of Sciences - PNAS, 2006-02, Vol.103 (9), p.3410-3415

2006

Link zum Volltext

Verfügbarkeit prüfen

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

The lancet oncology, 2017-11, Vol.18 (11), p.1483-1492

2017

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

Journal of clinical oncology, 2020-08, Vol.38 (23), p.2658-2666

2020

Link zum Volltext

Verfügbarkeit prüfen

Pharmacological Inhibition of O-GlcNAcase Does Not Increase Sensitivity of Glucocorticoid Receptor-Mediated Transrepression

PloS one, 2015-12, Vol.10 (12), p.e0145151-e0145151

2015

Link zum Volltext

Verfügbarkeit prüfen

A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid

The Journal of neuroscience, 2014-02, Vol.34 (8), p.2884-2897

2014

Link zum Volltext

Verfügbarkeit prüfen

Advances in the development of kinase inhibitor therapeutics for Alzheimer's disease

Drug development research, 2009-03, Vol.70 (2), p.125-144

2009

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans

Drug metabolism and disposition, 2015-06, Vol.43 (6), p.851-863

2015

Link zum Volltext

Verfügbarkeit prüfen

Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease

Journal of neuroscience research, 2012-12, Vol.90 (12), p.2247-2258

2012

Link zum Volltext

Verfügbarkeit prüfen

Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort

Journal of Alzheimer's disease, 2015-01, Vol.46 (2), p.431

2015

Link zum Volltext

Verfügbarkeit prüfen

CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition

The Journal of neuroscience, 2014-06, Vol.34 (24), p.8336-8346

2014

Link zum Volltext

Verfügbarkeit prüfen

Systems Pharmacology Analysis of the Amyloid Cascade after β-Secretase Inhibition Enables the Identification of an Aβ42 Oligomer Pool

The Journal of pharmacology and experimental therapeutics, 2016-04, Vol.357 (1), p.205

2016

Link zum Volltext

Verfügbarkeit prüfen

Activation of c-Jun N-Terminal Kinase and p38 in an Alzheimer's Disease Model Is Associated with Amyloid Deposition

The Journal of neuroscience, 2002-05, Vol.22 (9), p.3376-3385

2002

Link zum Volltext

Verfügbarkeit prüfen

Pyroglutamate-Modified Amyloid-β Protein Demonstrates Similar Properties in an Alzheimer's Disease Familial Mutant Knock-In Mouse and Alzheimer's Disease Brain

Neuro-degenerative diseases, 2014-01, Vol.14 (2), p.53-66

2014

Link zum Volltext

Verfügbarkeit prüfen

A Machine Learning Approach to Identify a Circulating MicroRNA Signature for Alzheimer Disease

The journal of applied laboratory medicine, 2020-01, Vol.5 (1), p.15-28

2020

Link zum Volltext

Verfügbarkeit prüfen

A transgenic rat model of Alzheimer's disease with extracellular Aβ deposition

Neurobiology of aging, 2009-07, Vol.30 (7), p.1078-1090

2009

Link zum Volltext

Verfügbarkeit prüfen

Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex

Journal of neuroscience research, 2011-06, Vol.89 (6), p.822-832

2011

Link zum Volltext

Verfügbarkeit prüfen

Adenosine analogue inhibitors of S-adenosylhomocysteine hydrolase

Bioorganic & medicinal chemistry letters, 2014-06, Vol.24 (12), p.2737-2740

2014

Link zum Volltext

Verfügbarkeit prüfen

CEP-1347 (KT7515), a Semisynthetic Inhibitor of the Mixed Lineage Kinase Family

The Journal of biological chemistry, 2001-07, Vol.276 (27), p.25302-25308

2001

Link zum Volltext

Verfügbarkeit prüfen

Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease

Neurobiology of aging, 2006-03, Vol.27 (3), p.377-386

2006

Link zum Volltext

Verfügbarkeit prüfen

Protein Tyrosine Phosphatases Are Up-regulated and Participate in Cell Death Induced by Polyglutamine Expansion

The Journal of biological chemistry, 2002-11, Vol.277 (46), p.44208-44213

2002

Link zum Volltext

Verfügbarkeit prüfen

Abeta oligomers as a pharmacodynamic biomarker of secretase therapy in Alzheimer's disease?

Alzheimer's & dementia, 2015-07, Vol.11 (7), p.P325-P325

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 329

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(310)
Mit Volltextzugriff
(296)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

Discovery of MK-8719, a Potent O‑GlcNAcase Inhibitor as a Potential Treatment for Tauopathies

Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy

Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort

AMPA Receptor Downscaling at the Onset of Alzheimer's Disease Pathology in Double Knockin Mice

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

Pharmacological Inhibition of O-GlcNAcase Does Not Increase Sensitivity of Glucocorticoid Receptor-Mediated Transrepression

A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid

Advances in the development of kinase inhibitor therapeutics for Alzheimer's disease

Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans

Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease

Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort

CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition

Systems Pharmacology Analysis of the Amyloid Cascade after β-Secretase Inhibition Enables the Identification of an Aβ42 Oligomer Pool

Activation of c-Jun N-Terminal Kinase and p38 in an Alzheimer's Disease Model Is Associated with Amyloid Deposition

Pyroglutamate-Modified Amyloid-β Protein Demonstrates Similar Properties in an Alzheimer's Disease Familial Mutant Knock-In Mouse and Alzheimer's Disease Brain

A Machine Learning Approach to Identify a Circulating MicroRNA Signature for Alzheimer Disease

A transgenic rat model of Alzheimer's disease with extracellular Aβ deposition

Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex

Adenosine analogue inhibitors of S-adenosylhomocysteine hydrolase

CEP-1347 (KT7515), a Semisynthetic Inhibitor of the Mixed Lineage Kinase Family

Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease

Protein Tyrosine Phosphatases Are Up-regulated and Participate in Cell Death Induced by Polyglutamine Expansion

Abeta oligomers as a pharmacodynamic biomarker of secretase therapy in Alzheimer's disease?

Suchergebnisse filtern